Potent compound manufacturing in the pharmaceutical pilot plant

Pharmaceutical Engineering

Volumn 18, Issue 5, 1998, Pages 8-22

  Chung, Jihchin ^a,b,c,d,e,f   Brookes Jr , A Sidney ^a,e,g,h   Cooke, Mary F ^a,e,i,j   Hrytsak, Michael D ^a,e,f,k,l  

^a DUPONT COMPANY   (United States)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NORTHWESTERN UNIVERSITY   (United States)

^d JOHNSON AND JOHNSON   (United States)

^e Johnson and Johnson ^*

^f ACS

^g YALE UNIVERSITY   (United States)

^h St Luke's Sinai Samaritan Med C

ⁱ BUCKNELL UNIVERSITY   (United States)

^j Johnson Matthey   (United States)

^k LAURENTIAN UNIVERSITY   (Canada)

^l UNIVERSITY OF OTTAWA   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; FIBRINOGEN RECEPTOR ANTAGONIST; FLUOROURACIL; METHOTREXATE; PARACETAMOL; ROXIFIBAN; UNCLASSIFIED DRUG; WARFARIN;

COST CONTROL; DRUG BIOAVAILABILITY; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG POTENCY; DRUG SAFETY; EQUIPMENT; REVIEW; TECHNOLOGY;

EID: 0031706468     PISSN: 02738139     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (4)

1. F. Fisher-Tyler, "Performance-Based Levels of Exposure Control Engineering Guide No. 94-1," DuPont Pharmaceuticals internal document, (1994).
2. B.D. Naumann, E.V. Sargent, B.S. Starkman, W. J. Fraser, G.T. Becker and G.D. Kirk, "Performance-Based Exposure Control Limits for Pharmaceutical Active Ingredients," American Industrial Hygiene Association Journal, 57: 33-42 (1996).
3. G. J. Cerulli, "Strategies for the Containment of Potent Compounds in Pilot and Clinical Trials Facilities," presented at 1996 AIChE Annual Meeting, Chicago, November 14, 1996.
4. H. Rahe, "Consider Barrier/Isolation Technology for Batches," Chemical Engineering Progress, p. 72-75, December, 1996.